AUTL | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 31%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

5.96%

1 Month

11.89%

3 Months

0.63%

6 Months

11.89%

1 Year

-17.53%

2 Year

-70.43%

Key data

Stock price

$1.60

P/E Ratio

0.00

DAY RANGE

$1.58 - $1.70

EPS

-$0.83

52 WEEK RANGE

$1.10 - $2.70

52 WEEK CHANGE

-$19.19

MARKET CAP

433.810 M

YIELD

N/A

SHARES OUTSTANDING

266.143 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

2.14

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,607,395

AVERAGE 30 VOLUME

$1,634,924

Company detail

CEO: Christian M. Itin
Region: US
Website: autolus.com
Employees: 330
IPO year: 2018

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.

AUTL - Autolus Therapeutics plc